Director at Globus Medical (NYSE: GMED) gets 15,000 stock options

Rhea-AI Filing Summary

Globus Medical director Leslie V. Norwalk received a grant of 15,000 stock options for Class A common stock. The options carry an exercise price of $94.15 per share and were granted as a derivative equity award.

According to the filing, these options were granted on January 21, 2026, will vest on January 1, 2027, and expire on January 21, 2036. After this grant, Norwalk beneficially owns 15,000 derivative securities directly, reflecting a standard director compensation award rather than an open-market transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norwalk Leslie V

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$94.15	01/21/2026		A		15,000		(1)	01/21/2036	Class A Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. These options were granted on January 21, 2026, and will vest on January 1, 2027.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Globus Medical (GMED) report for Leslie V. Norwalk?

The company reported that director Leslie V. Norwalk received a grant of 15,000 stock options for Class A common stock as a derivative equity award.

What is the exercise price of the new stock options reported for GMED?

The stock options granted to Leslie V. Norwalk have an exercise price of $94.15 per share for Globus Medical Class A common stock.

When do Leslie V. Norwalks Globus Medical (GMED) options vest and expire?

The options were granted on January 21, 2026, will vest on January 1, 2027, and will expire on January 21, 2036, if not exercised earlier.

How many Globus Medical derivative securities does Leslie V. Norwalk own after this grant?

After the reported transaction, Leslie V. Norwalk beneficially owns 15,000 derivative securities (stock options) directly.

Is the Globus Medical (GMED) Form 4 transaction a purchase or a grant?

The Form 4 reflects an option grant (transaction code A) to the director, not an open-market stock purchase or sale.

Does Leslie V. Norwalk hold the Globus Medical options directly or indirectly?

The filing shows the 15,000 stock options as held with direct ownership (D) by Leslie V. Norwalk.